Vedanta Biosciences Secures $60 Million in Funding and Strengthens Leadership Team Ahead of Pivotal Phase 3 Data (Business Wire)

Microbiome therapeutics developer Vedanta Biosciences has secured $60 million in new funding as it advances its lead candidate, VE303, through Phase 3 clinical trials for recurrent Clostridioides difficile infection (CDI). The financing comes as the pivotal RESTORATiVE303 study surpasses 80% enrollment, with topline efficacy data expected in the first half of 2027. Designed as a defined, orally administered live biotherapeutic, VE303 aims to restore the gut microbiome and prevent recurrent CDI without relying on donor fecal material. The investment, coupled with new leadership appointments, signals continued confidence in microbiome-based therapeutics as a promising frontier for treating gastrointestinal diseases.